Edgewise Therapeutics, Inc. 10-K

Item 7A. Quantitative and Qualitative Disclosures About Market Risk We were a smaller reporting company as defined by Rule 12b‑2 of the Exchange Act in 2024 and are not required to provide the information under this item in compliance with certain scaled disclosure requirements available to smaller reporting companies. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 129 Table of Contents